Pfizer (PFE) Intangibles (2009 - 2026)

Pfizer has disclosed Intangibles across 18 years of filings, most recently posting $52.6 billion for Q1 2026.

• In Q1 2026, Intangibles fell 2.63% year-over-year to $52.6 billion; the TTM figure through Mar 2026 stood at $52.6 billion (down 2.63% YoY), while the FY2025 annual figure was $53.7 billion, down 3.03% from the prior year.
• Intangibles slipped to $52.6 billion in Q1 2026, from $53.7 billion in the prior quarter.
• Over the last five years, Intangibles for PFE reached as high as $64.9 billion in Q4 2023 and fell as low as $28.2 billion in Q4 2022.
• The 5-year median for Intangibles is $52.6 billion (2026), against an average of $48.4 billion.
• Annual changes were most pronounced in 2022 — Intangibles jumped 72.47% — and 2024, when it declined 14.62%.
• A 5-year view of Intangibles shows it stood at $43.4 billion in 2022, then jumped by 49.64% to $64.9 billion in 2023, then slipped by 14.62% to $55.4 billion in 2024, then retreated by 3.03% to $53.7 billion in 2025, then fell by 2.18% to $52.6 billion in 2026.
• According to Business Quant data, Intangibles over the past three periods registered $52.6 billion, $53.7 billion, and $51.3 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.